Cytiva Acquires Vanrx; Sai Life Sciences To Expand; Recipharm in JV
The latest from CDMOs, CMOs, and suppliers featuring Cytiva, Sai Life Sciences, Recipharm, and Medspray.
Chemicals/Chemical API Manufacturing
Sai Life Sciences To Expand API Development, Mfg in the UK
Sai Life Sciences, a Hyderabad, India-headquartered CDMO of intermediates and active pharmaceutical ingredients (APIs) and discovery chemistry services, has announced plans to expand its API development and manufacturing at its Manchester, UK site.
In August 2020, the Manchester site became fully operational and on-boarded 24 members of staff. The upcoming expansion involves an increase in capacity from 20 to 75 fume cupboards and an increase in employees from 24 to 50+ scientists. A further expansion will see the addition of a GMP kilo Lab later in 2021. The company recently commenced recruitment for multiple positions across API process and analytical research & development, particle sciences, and engineering.
Sai Life Sciences is investing over $150 million between 2019 and 2023 across three core areas: (1) people & culture; (2) processes & automation; and (3) infrastructure & scientific capabilities.
Source: Sai Life Sciences
Formulation Development/Drug-Product Manufacturing
Cytiva Acquires Canadian Aseptic Filling Company, Vanrx Pharmasystems
Cytiva, the new name of GE Healthcare Life Sciences following Danaher’s $21.4-billion acquisition of GE Healthcare Life Sciences in April 2020, has acquired Vanrx Pharmasystems, a British Columbia, Canada-based company that makes robotic aseptic filling machines to fill vials, syringes, and cartridges.
Vanrx’s flagship products are the SA25 Aseptic Filling Workcell and Microcell Vial Filler, which automate aseptic filling using robotics within closed, gloveless isolators.
This is Cytiva’s first acquisition since becoming a Danaher operating company. Vanrx was founded in 2007 and currently has over 120 employees, all of whom have been offered employment with Cytiva.
Source: Cytiva
Recipharm, Medspray Launch JV for Softmist Sprays
Recipharm, a CDMO of active pharmaceutical ingredients (APIs) and drug products, and Medspray, a manufacturer of spray nozzles, have agreed to establish a joint venture, known as Resyca BV, to develop softmist spray nozzle technology for pharmaceutical applications.
Under this agreement, Recipharm will invest EUR 15 million ($18 million) in return for 51% of the shares of Resyca. Medspray will transfer its softmist intellectual property relating to pharmaceutical applications into Resyca.
Recipharm’s investment in Resyca has been made through its subsidiary Recipharm BV. Resyca will operate development facilities in Munich, Germany, and spray nozzles will be supplied exclusively from Medspray in The Netherlands. The companies say that commercial supply of finished devices will be manufactured and supplied by other Recipharm affiliates including the specialist device manufacturing capabilities located in King’s Lynn, UK. Additionally, Recipharm will receive an exclusive license for the development and manufacturing of syringe-based devices using the softmist nozzle technology, which will be marketed by Recipharm under the brand Bespak by Recipharm.
